Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Evotec AG (EVO) vs Ironwood Pharmaceuticals, Inc. (IRWD)

Evotec AG and Ironwood Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Ironwood Pharmaceuticals, Inc. is the larger, with a market value of $692.4M against $539.9M — 1.3× the size. Evotec AG has negative trailing earnings, so its P/E is not meaningful; Ironwood Pharmaceuticals, Inc. trades at 5.2×. Ironwood Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 26.2% against 2.15%. Ironwood Pharmaceuticals, Inc. has the higher net margin (33.4% vs −26.2%) and the higher return on invested capital (101.6% vs 0.00%). Across the 18 metrics below, Ironwood Pharmaceuticals, Inc. leads on 12 and Evotec AG on 6.

Valuation

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
P/E n/m 5.18 20.14
P/S 0.64 1.74 2.25
P/B 0.72 n/m 1.90
Price to free cash flow n/m 3.66 16.54
EV/EBITDA n/m 5.02 12.29
EV/Sales 0.65 3.04 2.56
Earnings yield (40.90%) 19.31% (2.99%)
Free cash flow yield (36.14%) 27.32% 0.00%

Profitability

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
Gross margin 11.42% 100.00% 53.94%
Operating margin (21.35%) 60.15% 0.00%
Net margin (26.20%) 33.36% 0.00%
Free cash flow margin 0.00% 47.66% 0.00%
Return on equity 0.00% (55.26%) (0.40%)
Return on assets 0.00% 41.35% (3.32%)
Return on invested capital 0.00% 101.61% 0.00%

Growth

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 2.15% 26.19% 10.01%
EPS growth (last fiscal year) 44.89% 2,627.27% —
Revenue growth, 5-year CAGR 9.28% (5.33%) 6.74%
Net income growth, 5-year CAGR 0.00% (25.72%) 0.00%

Health

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
Debt to equity 0.72 (2.38) 0.05
Current ratio 2.33 6.06 2.31
Net debt to EBITDA (0.64) 3.68 0.85

Dividend

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric EVO IRWD Drug Manufacturers Specialty & Generic median
Market cap 539.87m 692.36m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack